PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1403
https://www.valueinhealthjournal.com/article/S1098-3015(12)03116-6/fulltext
Title :
PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03116-6&doi=10.1016/j.jval.2012.08.1403
First page :
A448
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
903